Latest Industry Insights
Industry Insight
The Development of Plant-Based Medicines for Prescription
Despite the fact that herbal or plant-based medicines are widely used and trusted by the public and have been for many years, few have been approved by regulatory agencies in the Western world as prescription medicines. But why have so few botanical medicines been approved?
Industry Insight
180 Life Sciences: Developing Drugs To Tackle Distinct Inflammatory Diseases
180 Life Sciences is exploring the use of synthetic cannabidiol (CBD) analogs as a treatment strategy for inflammation and pain, and conducting clinical research focused on repurposing anti-tumor necrosis factor across different fibrotic conditions. Technology Networks recently spoke with Dr James Woody, chief executive officer at 180 Life Sciences, to find out more about the company's research and development pipeline.
Industry Insight
Exploiting the Therapeutic Potential of Plants
Technology Networks recently interviewed Viswa Colluru, founder and CEO of Enveda Biosciences, to find out how the company is “harnessing the complexity of the natural world to tackle today’s biggest healthcare challenges”.
Industry Insight
A “Losing” Proposition: Tackling the Problem of Lost or Unrecovered Analytes in Chromatography
Liquid chromatography has proven to be an invaluable tool in analytical labs. However, despite being a “mature” technique, there are still some areas that prove problematic, leading to suboptimal results. One such area is the loss of analytes during the chromatographic process, but design innovations are aiming to overcome this problem.
Industry Insight
Why Patient-Generated Health Data Could Power the Next Era of Clinical Research
Leveraging patient-generated health data (PGHD) in healthcare and clinical trials has become significantly easier with the advent of digitalization. We spoke to Alison Bourke, scientific director for real world insights at IQVIA and past president of the International Society for Pharmacoepidemiology, about how PGHD is collected, why it is useful and how we can best safeguard sensitive data.
Industry Insight
Cytisinicline: A Treatment To Help People Battling Nicotine Addiction
The pharmaceutical company Achieve Life Sciences is focused on addressing one of the biggest public health threats globally – tobacco use. Technology Networks had the pleasure of speaking with the company's chief medical officer Cindy Jacobs, MD, PhD, to learn more about cytisinicline, a plant-based alkaloid the company is currently developing as a smoking cessation treatment.
Industry Insight
Behind the World-First Export of Jamaican Psilocybin Mushrooms
Mydecine Innovations Group recently announced that it had completed the first harvest and commercial export of legal psychedelic psilocybin mushrooms from Jamaica to Canada. We spoke with Mydecine’s chief scientific officer and co-founder, Rob Roscow, to find out more.
Industry Insight
Meeting Renewed Regulatory Focus on Gene Therapy Safety Standards
In this industry insights piece, we explore how gene therapies represent a rapidly growing new paradigm — both therapeutically and with respect to how they are managed within the larger scope of healthcare — and how this has wide-ranging impacts on several key areas, including regulation.
Industry Insight
Eliciting the Hormetic Effect: The Importance of Plant Alkaloids for Treatment of Inflammation
Today, plant alkaloids are attracting notice as novel therapies for conditions involving inflammation, such as metabolic syndrome, autoimmune disease and even for aging, which are often characterized by chronic, low-grade over-activation of the immune system. This piece takes a closer look at the need for novel treatments and the best uses for plant alkaloids.
Industry Insight
PCR: The "Workhorse" Technology
Technology Networks spoke with Dr Jan Hellemans, CTO and co-founder of CRO Biogazelle, as well as co-author of the MIQE guidelines, to learn why PCR-based technologies are the "workhorse" technologies for the company.
Advertisement